Smith & Nephew stock

SN. · LSE · GBp

Compare Smith & Nephew
1,145.00 GBpChange from previous close: +0.88%Absolute change: +10.00 GBp

Close · November 20, 2026

Price history

−6.99% over the period

1 year: from 1,231.00 GBp (November 20, 2025) to 1,145.00 GBp (November 20, 2026), −6.99%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 20261,145.00 GBp
October 30, 20261,107.50 GBp
September 30, 20261,009.00 GBp
August 28, 20261,062.50 GBp
July 31, 20261,158.50 GBp
June 30, 20261,090.50 GBp
May 29, 20261,111.00 GBp
April 30, 20261,137.00 GBp
March 31, 20261,185.00 GBp
February 27, 20261,371.50 GBp
January 30, 20261,242.00 GBp
December 31, 20251,238.50 GBp
November 28, 20251,254.50 GBp
November 20, 20251,231.00 GBp

At a glance

  • The company

    Develops, manufactures and markets medical devices for orthopaedic surgery, sports medicine, ENT and advanced wound management

  • Latest results

    Quarter to June 30, 2026 · EPS $0.47 (estimate $0.47)

TickerLandia's take on Smith & Nephew

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low980.40 GBp
52-wk high1,396.50 GBp

−18.01% from the 52-week high

Analysts · 18 analysts

Average target1,256.53 GBp+9.74% vs. price

Buy 4 · Hold 13 · Sell 1 · Hold

TickerLandia Fingerprint: Smith & Nephew

Compared with similar companies: very low price.

Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Smith & Nephew is cheaper than similar companies

Smith & Nephew's P/E (trailing 12 months): 20.8, −27% against the median of a group of 10 similar companies (28.3).

Compared with 10 similar companies

Smith & Nephew's metrics compared with similar companies
MetricSmith & NephewPosition in the groupBand
P/E (trailing 12 months)20.8Low
Forward P/E13.2Low
Operating margin14.2%Middle
ROE11.9%Middle
Debt/equity0.73Middle

Grey band: the middle half of the group; tick: the median; dot: Smith & Nephew. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$3.1B

Latest quarter · Q2 2026

Net income

$303M

Latest quarter · Q2 2026

Quarterly net margin

9.8%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
£9.57B
P/E
20.8
EPS
55.00 GBp
Volume
3.01M
Daily trading
€57.53M
Dividend yield
2.57%
Last ex-dividend on October 1, 2026

How Smith & Nephew is changing

All results
  • Revenue grew 6.2% a year on average over the last 5 years

  • Operating margin rose from 12.6% to 14.2%

  • Profits turn into cash: free cash flow equal to 126% of net income

Returns

Smith & Nephew returns with dividends

£1,000 invested in Smith & Nephew 5 years ago, on November 22, 2021, would be worth £1,030 today with dividends reinvested: +3.05% in total, +0.60% per year. On price alone it would be £900 (−10.02%).

PeriodSmith & NephewFTSE 100£1,000 becomes
1 month+5.29%−3.60%£1,053
6 months0.00%−0.82%£1,000
Year to date−7.55%+4.18%£925
1 year−4.48%+8.59%£955
3 years+21.58%+38.02%£1,216
5 years+3.05%+42.60%£1,030
10 years+31.84%+52.65%£1,318

Over the last 6 months it has done better than 22% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE 100: price only. Calculate your investment

The chart in detail

Smith & Nephew: technical analysis

Smith & Nephew shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 42.5% below its highest close since January 1, 1990 (1,990.00 GBp, September 2, 2019).

Trend
No clear trend
RSI (14 sessions)
55
Between 30 and 70
vs 200-session average
−0.13%

Support and resistance

Price areas where Smith & Nephew has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance1,208.20 GBp+5.52%5 touches, last on November 5, 2026
  2. Resistance1,179.04 GBp+2.97%4 touches, last on July 17, 2026
  3. Resistance1,163.13 GBp+1.58%4 touches, last on October 23, 2026
  4. Last price1,145.00 GBp
  5. Support1,104.75 GBp−3.52%2 touches, last on July 23, 2026
  6. Support1,080.50 GBp−5.63%4 touches, last on November 4, 2026
  7. Support1,048.00 GBp−8.47%2 touches, last on August 21, 2026

Volatility and risk

Over the last year it has moved less than the FTSE 100.

Beta (1 year) vs FTSE 100
0.49
Volatility (60 sessions, annualised)
26.1%
Largest fall in the last year
−28.37%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Smith & Nephew: seasonality

Average monthly price change over 37 years

+0.3%Jan+2.4%Feb−1.9%Mar+1.8%Apr+0.0%May+0.8%Jun+0.5%Jul+0.6%Aug−0.6%Sep−0.5%Oct+1.3%Nov+3.2%Dec

Over the last 37 years, the strongest month for Smith & Nephew has been December: +3.24% on average, positive in 22 years out of 36. The weakest has been March: −1.86% on average, positive in 13 years out of 37. November, the current month, has been positive in 19 years out of 36 (+1.32% on average).

Show chart data
MonthAverageMedianPositive years
January+0.33%−0.16%15 of 36
February+2.43%+2.31%22 of 37
March−1.86%−2.13%13 of 37
April+1.78%+0.70%19 of 37
May+0.01%−0.08%16 of 37
June+0.78%0.00%18 of 37
July+0.53%−0.38%15 of 37
August+0.62%−0.93%15 of 37
September−0.61%−0.31%14 of 37
October−0.52%−1.04%15 of 37
November+1.32%+0.49%19 of 36
December+3.24%+3.71%22 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Smith & Nephew and its competitors

Smith & Nephew's largest business is its Orthopaedics segment, which covers knee and hip implants, trauma and extremities products for the stabilization of severe fractures, and other reconstruction products. Its other two segments are Sports Medicine & ENT, offering minimally invasive joint repair instruments, arthroscopic enabling technologies and ear, nose and throat solutions, and Advanced Wound Management, which includes wound care products, bioactives and regenerative medicine products, and negative pressure wound therapy and hydrosurgery systems.

Headquarters
Watford, United Kingdom
Employees
17,000
Founded
1856
Chief executive
Deepak Nath
Smith & Nephew and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Smith & NephewSN.$12.57B14.2%20.80.00%
DemantDEMANT$10.7B17.2%30.1+44.56%
Sonova HoldingSOON$20.67B20.6%28.9+43.74%
GetingeGETI.B$7.39B14.3%26.6+40.54%
SectraSECT.B$6.24B20.6%105.8+21.58%
Koninklijke PhilipsPHIA$28.35B8.8%26.7+15.14%

Same industry or related industries, similar size. Compare Smith & Nephew with its competitors · Full profile